PMID- 23317233
OWN - NLM
STAT- MEDLINE
DCOM- 20130702
LR  - 20231213
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 13
IP  - 11
DP  - 2012
TI  - ppGalNAc T1 as a potential novel marker for human bladder cancer.
PG  - 5653-7
AB  - OBJECTIVES: To investigate the effect of glycopeptide-preferring polypeptide 
      GalNAc transferase 1 (ppGalNAc T1) targeted RNA interference (RNAi) on the growth 
      and migration of human bladder carcinoma EJ cells in vitro and in vivo. METHODS: 
      DNA microarray assays were performed to determine ppGalNAc Ts(ppGalNAc T1-9) 
      expression in human bladder cancer and normal bladder tissues. We transfected the 
      EJ bladder cancer cell line with well-designed ppGalNAc T1 siRNA. Boyden chamber 
      and Wound healing assays were used to investigate changes of shppGalNAc T1-EJ 
      cell migration. Proliferation of shppGalNAc T1-EJ cells in vitro was assessed 
      using [3H]-thymidine incorporation assay and soft agar colony formation assays. 
      Subcutaneous bladder tumors in BALB/c nude mice were induced by inoculation of 
      shppGalNAc T1-EJ cells and after inoculation diameters of tumors were measured 
      every 5 days to determine gross tumor volumes. RESULTS: ppGalNAc T1 mRNA in 
      bladder cancer tissues was 11.2-fold higher than in normal bladder tissues. When 
      ppGalNAc T1 expression in EJ cells was knocked down through transfection by 
      pSUPER-shppGalNAc T1 vector, markedly reduced incorporation of [3H]-thymidine 
      into DNA of EJ cells was observed at all time points compared with the empty 
      vector transfected control cells. However, ppGalNAc T1 knockdown did not 
      significantly inhibited cell migration (only 12.3%). Silenced ppGalNAc T1 
      expression significantly inhibited subcutaneous tumor growth compared with the 
      control groups injected with empty vector transfected control cells. At the end 
      of observation course (40 days), the inhibitory rate of cancerous growth for 
      ppGalNAc T1 knockdown was 52.5%. CONCLUSION: ppGalNAc T1 might be a potential 
      novel marker for human bladder cancer. Although ppGalNAc T1 knockdown caused no 
      remarkable change in cell migration, silenced expression significantly inhibited 
      proliferation and tumor growth of the bladder cancer EJ cell line.
FAU - Ding, Ming-Xia
AU  - Ding MX
AD  - Department of Urology, The Second Affiliated Hospital of Kunming Medical 
      University, Yunnan Institute of Urology, Kunming, China E-mail : 
      jiansongwang@126.com.
FAU - Wang, Hai-Feng
AU  - Wang HF
FAU - Wang, Jian-Song
AU  - Wang JS
FAU - Zhan, Hui
AU  - Zhan H
FAU - Zuo, Yi-Gang
AU  - Zuo YG
FAU - Yang, De-Lin
AU  - Yang DL
FAU - Liu, Jing-Yu
AU  - Liu JY
FAU - Wang, Wei
AU  - Wang W
FAU - Ke, Chang-Xing
AU  - Ke CX
FAU - Yan, Ru-Ping
AU  - Yan RP
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Small Interfering)
RN  - EC 2.4.1.- (N-Acetylgalactosaminyltransferases)
SB  - IM
MH  - Animals
MH  - Apoptosis
MH  - Biomarkers, Tumor/genetics/*metabolism
MH  - Blotting, Western
MH  - *Cell Movement
MH  - *Cell Proliferation
MH  - Colony-Forming Units Assay
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - N-Acetylgalactosaminyltransferases/antagonists & inhibitors/genetics/*metabolism
MH  - RNA, Messenger/genetics
MH  - RNA, Small Interfering/genetics
MH  - Real-Time Polymerase Chain Reaction
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Urinary Bladder/*metabolism
MH  - Urinary Bladder Neoplasms/genetics/metabolism/*pathology
MH  - Polypeptide N-acetylgalactosaminyltransferase
EDAT- 2013/01/16 06:00
MHDA- 2013/07/03 06:00
CRDT- 2013/01/16 06:00
PHST- 2013/01/16 06:00 [entrez]
PHST- 2013/01/16 06:00 [pubmed]
PHST- 2013/07/03 06:00 [medline]
AID - 10.7314/apjcp.2012.13.11.5653 [doi]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2012;13(11):5653-7. doi: 10.7314/apjcp.2012.13.11.5653.